NCT03359863View on ClinicalTrials.gov

Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 7, 2018

Primary Completion Date

October 28, 2021

Study Completion Date

October 28, 2021

Conditions
Restrictive Chronic Lung Allograft DysfunctionLung Transplant Rejection
Interventions
DRUG

Pirfenidone

Subjects will receive pirfenidone for 52 weeks, titrated to 2403 mg/day (3 capsules, 3× daily) after a 4-week titration period (1 capsule, 3x daily for 2 weeks, 2 capsules, 3x daily for 2 weeks) for a total of 56 weeks of pirfenidone. Eligible participants will continue pirfenidone beyond 56 weeks.

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT03359863 - Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction | Biotech Hunter | Biotech Hunter